Ascelia Pharma AB
STO:ACE

Watchlist Manager
Ascelia Pharma AB Logo
Ascelia Pharma AB
STO:ACE
Watchlist
Price: 4.515 SEK 4.03% Market Closed
Market Cap: 523.9m SEK

Intrinsic Value

ACE's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one ACE stock under the Base Case scenario is 33.399 SEK. Compared to the current market price of 4.515 SEK, Ascelia Pharma AB is Undervalued by 86%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ACE Intrinsic Value
33.399 SEK
Undervaluation 86%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Ascelia Pharma AB

Valuation History Unavailable

Historical valuation for ACE cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare ACE to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ACE?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Ascelia Pharma AB
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ascelia Pharma AB

Current Assets 64.5m
Cash & Short-Term Investments 57.3m
Receivables 3.9m
Other Current Assets 3.3m
Non-Current Assets 58.5m
PP&E 1.4m
Intangibles 57.1m
Efficiency

Free Cash Flow Analysis
Ascelia Pharma AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Ascelia Pharma AB

Revenue
0 SEK
Operating Expenses
-71.4m SEK
Operating Income
-71.4m SEK
Other Expenses
-13.7m SEK
Net Income
-85.1m SEK
Fundamental Scores

ACE Profitability Score
Profitability Due Diligence

Ascelia Pharma AB's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Ascelia Pharma AB's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ACE Solvency Score
Solvency Due Diligence

Ascelia Pharma AB's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
44/100
Solvency
Score

Ascelia Pharma AB's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ACE Price Targets Summary
Ascelia Pharma AB

Wall Street analysts forecast ACE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACE is 11.22 SEK with a low forecast of 11.11 SEK and a high forecast of 11.55 SEK.

Lowest
Price Target
11.11 SEK
146% Upside
Average
Price Target
11.22 SEK
149% Upside
Highest
Price Target
11.55 SEK
156% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Ascelia Pharma AB
does not pay dividends
Shareholder Yield

Current shareholder yield for ACE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ACE Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ACE stock?

The intrinsic value of one ACE stock under the Base Case scenario is 33.399 SEK.

Is ACE stock undervalued or overvalued?

Compared to the current market price of 4.515 SEK, Ascelia Pharma AB is Undervalued by 86%.

Back to Top